Summary: Researchers say their findings about immune system changes early in Alzheimer’s could lead to new blood tests that may be used to detect the disease before it becomes symptomatic.

Source: University of Colorado Anschutz Medical Campus.

An association between inflammation biomarkers in both blood plasma and cerebrospinal fluid (CSF) and markers of Alzheimer’s disease (AD) associated pathology, has been found by researchers at the University of Colorado Anschutz Medical Campus working with the University of Wisconsin Alzheimer’s Disease Research Center and the University of California San Francisco Memory and Aging Center.

The discovery sheds new light on the pathology of AD as well as on the communication between the brain and the rest of the body. The findings were published today in the Journal of Alzheimer’s Disease.

Scientists have long known that AD-related pathology may develop long before clinical symptoms of AD appear, and that inflammation is a core component of the disease. Previous studies have linked levels of inflammatory markers in CSF and blood to Mild Cognitive Impairment (MCI), and research shows that elevations in inflammatory markers may be present decades before any AD symptoms appear.

However, whether markers of inflammation in the blood (i.e., ‘peripheral’ inflammation) were related to known measures of AD-related pathology, even after accounting for CSF levels of inflammation (i.e., ‘central’ inflammation), remained unclear. Researchers also wanted to know whether markers of inflammation in blood plasma reflected inflammation of the central nervous system.

“One of the two primary goals of our study was to assess the association between inflammatory markers in CSF and plasma to clarify how well plasma inflammatory markers reflect central nervous system inflammation,” said study author Brianne Bettcher, PhD, assistant professor of neurosurgery and neurology at the University of Colorado School of Medicine. “Even more importantly, we were interested in determining whether inflammatory markers in plasma were independently linked to CSF markers of AD-related pathology and neuronal damage in a group of healthy, community dwelling older adults.”

Her team tested blood and CSF samples from 173 middle-aged and older adults enrolled in the Wisconsin Alzheimer’s Disease Research Center. Participants were healthy adults in that they had no clinical symptoms of Alzheimer’s disease, although some had family histories of dementia presumed due to AD.

The scientists had expected inflammation markers in the CSF to be more robust predictors of AD-related pathology and neuronal damage than those in the blood due to the `blood brain barrier.’

“Results from our study suggest that although CSF markers of inflammation are strong predictors, both plasma and CSF markers of inflammation independently relay information about AD-related pathology and neuronal damage in head-to-head comparisons,” Bettcher said.

The finding was unexpected.

“From my perspective, there has been a perception in the field that the blood and the ‘periphery’ are not related to the brain – that the brain and the rest of the body are completely separate,” Bettcher said. “I think increasing evidence suggests that the brain and body communicate. Our study shows that inflammation markers in the blood may be telling us about what is going on inside the brain.”

Recent animal studies have shown a strong relationship between elevated inflammation and the propagation of tau proteins, which are associated with AD.

Bettcher said the new findings could possibly serve as the focus of more in-depth studies aimed at developing a blood test to detect inflammation biomarkers years before symptoms of Alzheimer’s appear.

She says the study also points to a potentially early role for inflammation in aging and AD. Bettcher also emphasized that although participants had detectable levels of AD-related markers and markers of neuronal damage in their CSF, the presence of these markers alone does not indicate a diagnosis of AD, nor does it mean that they will develop AD in the future.

“These findings add to a growing body of literature underscoring an increasingly important relationship between systemic inflammation, central inflammation, and pathological outcomes,” she said.

About this neuroscience research article

Funding: The study involved researchers at University of Colorado Anschutz Medical Campus, the London School of Hygiene & Tropical Medicine, the University of Oxford and the University of Exeter, and was funded by the Medical Research Council, the National Institute for Health Research, Alzheimer’s Research UK, Dementias Platform UK, Dunhill Medical Trust, Epilepsy Research UK, Great Western Research, Health Foundation and the Patrick Berthoud Trust.

Source: David Kelly – University of Colorado Anschutz Medical Campus
Publisher: Organized by NeuroscienceNews.com.
Image Source: NeuroscienceNews.com image is in the public domain.
Original Research: Study will appear in Journal of Alzheimer’s Disease.

Cite This NeuroscienceNews.com Article

University of Colorado Anschutz Medical Campus “Immune System Dysfunction May Occur Early in Alzheimer’s.” NeuroscienceNews. NeuroscienceNews, 6 February 2018.
<http://neurosciencenews.com/alzheimers-immune-system-dysfunction-8442/>.

University of Colorado Anschutz Medical Campus (2018, February 6). Immune System Dysfunction May Occur Early in Alzheimer’s. NeuroscienceNews. Retrieved February 6, 2018 from http://neurosciencenews.com/alzheimers-immune-system-dysfunction-8442/

University of Colorado Anschutz Medical Campus “Immune System Dysfunction May Occur Early in Alzheimer’s.” http://neurosciencenews.com/alzheimers-immune-system-dysfunction-8442/ (accessed February 6, 2018).

Feel free to share this Neuroscience News.

Share This